in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
67<br />
prote<strong>in</strong>ase-activated ❚<br />
PAR2<br />
cellul ar<br />
Ref. 2323<br />
Ref. 2324<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (Hela cells)<br />
Measured product <strong>in</strong>tracellular [Ca 2+ ]<br />
Detection method fluorimetry<br />
Agonist effect Control tryps<strong>in</strong> (100 µM)<br />
Reference tryps<strong>in</strong> (EC 50 : 169 nM)<br />
Antagonist effect Stimulant tryps<strong>in</strong> (1 µM)<br />
Reference unavailable<br />
Kawabata, A. et al. (1999) J. Pharmacol. Exp. Ther., 288: 358-370.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.1%<br />
<br />
<br />
<strong>Cerep</strong><br />
services<br />
<br />
Receptors<br />
[GPCRs]<br />
<br />
<br />
<br />
❚ pur<strong>in</strong>ergic<br />
<br />
<br />
<br />
<br />
<br />
Ion<br />
channels<br />
P2Y - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0128<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
High-throughput profile<br />
Diversity profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
rat cerebral cortex<br />
[ 35 S]dATPαS (10 nM)<br />
10 nM<br />
dATPαS (10 µM)<br />
dATPαS (IC 50 : 20 nM)<br />
Simon, J. et al. (1995) Pharmacol. Toxicol., 76: 302-307.<br />
<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-10 -9 -8 -7 -6 -5 -4<br />
log [drug] (M)<br />
dATPαS<br />
ADPβS<br />
suram<strong>in</strong><br />
α,β-MeATP<br />
Transporters<br />
K<strong>in</strong>ases<br />
P2Y 1<br />
cellul ar<br />
Ref. 2132<br />
Ref. 2134<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (1321N1 cells)<br />
Measured product <strong>in</strong>tracellular [Ca 2+ ]<br />
Detection method fluorimetry<br />
Agonist effect Control MRS 2365 (100 nM)<br />
Reference MRS 2365 (EC 50 : 0.24 nM)<br />
Antagonist effect Stimulant MRS 2365 (1 nM)<br />
Reference MRS 2500 (IC 50 : 39.3 nM)<br />
Chhatriwala, M. et al. (2004) J. Pharmacol. Exp. Ther., 311: 1038-1043.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.1%<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Epigenetic &<br />
DNA-related<br />
enzymes<br />
Other<br />
enzymes<br />
P2Y 2<br />
cellul ar<br />
Ref. 2164<br />
Ref. 2167<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (1321N1 cells)<br />
Measured product <strong>in</strong>tracellular [Ca 2+ ]<br />
Detection method fluorimetry<br />
Agonist effect Control UTP (3 µM)<br />
Reference UTP (EC 50 : 60 nM)<br />
Antagonist effect Stimulant UTP (300 nM)<br />
Reference unavailable<br />
Kassack, M.U. et al. (2002) J. Biomol. Screen., 7: 233-246.<br />
Ca 2+ mobilization (% of control)<br />
<br />
<br />
<br />
100 <br />
50<br />
0<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
-9 -8 -7 -6 -5<br />
-10 -4<br />
log [agonist] (M)<br />
UTP<br />
<br />
UDP<br />
MRS 2365<br />
2MeSADP<br />
[Solvent] must be kept ≤ 0.1%<br />
<br />
antagonist effect:<br />
no graph available<br />
<br />
Specialized<br />
cellular<br />
assays<br />
Standard<br />
profiles<br />
P2Y 4<br />
cellul ar<br />
Ref. 2165<br />
Ref. 2168<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (1321N1 cells)<br />
Measured product <strong>in</strong>tracellular [Ca 2+ ]<br />
Detection method fluorimetry<br />
Agonist effect Control UTP (100 nM)<br />
Reference UTP (EC 50 : 1.9 nM)<br />
Antagonist effect Stimulant UTP (10 nM)<br />
Reference unavailable<br />
Herold, C.L. et al. (2004) J. Biol. Chem., 279: 11456-11464.<br />
Ca 2+ mobilization (% of control)<br />
-12 -11<br />
-12 -11<br />
100 -12 -11<br />
50<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7 -6 -5<br />
0<br />
-11 -10<br />
-9 -8-12 -7 -11 -10 -6 -9-5<br />
-10 -8-4-7 -6 -5 -4<br />
-9 -8 -7 -6 -5 -4<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3<br />
antagonist effect:<br />
-10 -9 -8 -7<br />
no graph available<br />
log [agonist] (M)<br />
UTP<br />
UDP<br />
MRS 2365<br />
2MeSADP<br />
[Solvent] must be kept ≤ 0.1%<br />
Test<strong>in</strong>g<br />
conditions<br />
Order<strong>in</strong>g<br />
<strong>in</strong>formation<br />
-11 -10<br />
-9 -8 -7 -6 -5 -4<br />
For further details and updated <strong>in</strong>formation on assays:<br />
❚ Please go to www.cerep.com catalog onl<strong>in</strong>e or contact us at sales@cerep.com<br />
-12 -11<br />
-11 -10<br />
-12 -11<br />
-9 -8 -7 -6 -5 -4<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7 -6 -5<br />
-9 -8 -7 -6 -5<br />
-10 -4<br />
-11 -10<br />
-9 -8 -7 -6 -5 -4<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3<br />
❚ Europe: +33 (0)5 49 89 30 00 – USA: +1 (425) 895 8666 – Japan: +81 (0)3 3354 4026 – Ch<strong>in</strong>a: -12 -11+86 -10 -921 -8 5132 -7 0568<br />
Assay developed <strong>in</strong> 2010 New assay conditions Human Q Standard turnaround time<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4<br />
Assay list<br />
& <strong>in</strong>dex